
What is Claimed is:

1. A method of treating a proliferative disease in a human patient in need of such treatment, comprising administering to said human patient a compound of formula (I)



(I),

wherein W is CR_w or N, wherein

R_w is selected from the group consisting of:

(1) hydrogen,

(2) cyano,

(3) halogen,

(4) methyl,

5) trifluoromethyl,

(6) sulfonamide;

R_1 is selected from the group consisting of:

(1) hydrogen,

(2) cyano,

(3) nitro,

(4) halogen,

(5) substituted and unsubstituted alkyl,

(6) substituted and unsubstituted alkenyl,

(7) substituted and unsubstituted alkynyl,

(8) substituted and unsubstituted aryl,

(9) substituted and unsubstituted heteroaryl,

(10) substituted and unsubstituted heterocyclyl,

(11) substituted and unsubstituted cycloalkyl,

(12) $-COR_{1a}$,

(13) $-CO_2R_{1a}$,

(14) $-CONR_{1a}R_{1b}$,

(15) $-NR_{1a}R_{1b}$,

(16) $-NR_{1a}COR_{1b}$,

(17) $-NR_{1a}SO_2R_{1b}$,

(18) $-OCOR_{1a}$,

(19) $-OR_{1a}$,

(20) $-SR_{1a}$,

(21) $-SOR_{1a}$,

(23) $-SO_2NR_{1a}R_{1b}$ wherein

R_{1a}, and R_{1b} are independently selected from the group consisting of:

(a) hydrogen,

(b) substituted or unsubstituted alkyl,

(c) substituted and unsubstituted aryl,

(d) substituted and unsubstituted heteroaryl,

(e) substituted and unsubstituted heterocyclyl, and

(f) substituted and unsubstituted cycloalkyl;

R_2 is selected from the group consisting of:

(1) hydrogen,

(2) cyano,

(3) nitro,

(4) halogen,

(5) hydroxy,

(6) amino,

(7) substituted and unsubstituted alkyl,

(8) $-COR_{2a}$, and

(9) $-NR_{2a}COR_{2b}$, wherein

R_{2a}, and R_{2b} are independently selected from the group consisting of:

(a) hydrogen, and

(b) substituted or unsubstituted alkyl;

R_3 is selected from the group consisting of:

(1) hydrogen,

(2) cyano,

(3) nitro,

(4) halogen,

(5) substituted and unsubstituted alkyl,

(6) substituted and unsubstituted alkenyl,

(7) substituted and unsubstituted alkynyl,

(8) substituted and unsubstituted aryl,

(9) substituted and unsubstituted heteroaryl,

(10) substituted and unsubstituted heterocyclyl,

(11) substituted and unsubstituted cycloalkyl,

(12) $-COR_{3a}$,

(14) $-NR_{3a}R_{3b}$

(13) -$NR_{3a}COR_{3b}$,

(15) -$NR_{3a}SO_2R_{3b}$,

(16) -OR_{3a},

(17) -SR_{3a},

(18) -SOR_{3a},

(19) -SO_2R_{3a}, wherein

R_{3a}, and R_{3b} are independently selected from the group consisting of:

(a) hydrogen,

(b) substituted or unsubstituted alkyl,

(c) substituted and unsubstituted aryl,

(d) substituted and unsubstituted heteroaryl,

(e) substituted and unsubstituted heterocyclyl, and

(f) substituted and unsubstituted cycloalkyl; and

R_4 is selected from the group consisting of

(1) hydrogen, and

(2) halogen,

or a pharmaceutically acceptable salt thereof in a therapeutically effective amount of about 60 to about 120 mg daily for five consecutive days in any seven day period.

2. A method of treating a proliferative disease comprising first administering to a human patient in need thereof a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof in amount of about 60 to about 120 mg daily, second determining said patient has a condition selected from neutropenia, thrombocytopenia, serum creatine, elevated bilirubin, asymptomatic amylase and/or lipase elevation, mood alteration, neurotoxicity, hyperglycemia, rash, diarrhea, anorexia, nausea, fatigue, pneumonitis, pruritus and mucositis after administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof after administration of about 60 mg to about 120 mg daily to said human patient, and third reducing the dosage of said compound of formula (I) or a

pharmaceutically acceptable salt thereof to about 60 mg to about 120 mg daily for five consecutive days in any seven day period.

3. A method according to any one of claims 1 or 2, wherein the compound of formula (I) is 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine.

4. A method according to any one of claims 1 or 2, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a therapeutically effective amount of about 100 mg daily for five consecutive days in any seven day period.

5. A method according to any one of claims 1 or 2 wherein the proliferative disease is cancer.

6. A method according to claim 9, wherein the proliferative disease is a human cancer selected from the group consisting of lung and bronchus; prostate; breast; pancreas; colon and rectum; thyroid; liver and intrahepatic bile duct; hepatocellular; gastric; glioma/glioblastoma; endometrial; melanoma; kidney and renal pelvis; urinary bladder; uterine corpus; uterine cervix; ovary; head and neck; multiple myeloma; esophagus; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; melanoma; and villous colon adenoma.

7. A method according to any one of claims 1 or 2 wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional therapeutic agent.

8. Use of a compound of formula (I) according to claims 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in the treatment of a proliferative disease wherein the medicament comprising about 60 to about 120 mg of compound of formula (I) is administered to a human patient in need thereof for five consecutive days in any seven day period.

9. Use according to claims 8 wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a therapeutically effective amount of about 100 mg daily for five consecutive days in any seven day period.

10. Use according to claims 8 wherein the proliferative disease is cancer.

11. Use according to claim 8 wherein the proliferative disease is a human cancer selected from the group consisting of lung and bronchus; prostate; breast; pancreas; colon and

rectum; thyroid; liver and intrahepatic bile duct; hepatocellular; gastric; glioma/glioblastoma; endometrial; melanoma; kidney and renal pelvis; urinary bladder; uterine corpus; uterine cervix; ovary; head and neck; multiple myeloma; esophagus; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; melanoma; and villous colon adenoma.

12. Use according to claim 8 wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional therapeutic agent.

13. A therapeutic regimen comprising administering a compound of formula (I) according to claims 1 or 2 or a pharmaceutically acceptable salt thereof in an amount of about 60 to about 120 mg of compound of formula (I) or a pharmaceutically acceptable salt thereof for five consecutive days in any seven day period and wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional therapeutic agent.

14. A pharmaceutical composition for use in the treatment of a proliferative disease in a human patient in need thereof comprising an amount of about 60 to about 120 mg of a compound of formula (I) according to claims 1 or 2 or pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients which is administered for five consecutive days in any seven day period.

15. A package comprising the pharmaceutical composition comprising a compound of formula (I) according to claims 1 or 2 or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable pharmaceutically acceptable excipients in combination with instructions to administer said composition in an amount of about 60 mg to about 120 mg for five consecutive days in any seven day period.

Claims

1. An invention not claimed in any divisional application.